Details
Stereochemistry | ACHIRAL |
Molecular Formula | C27H31N2O6S2.Na |
Molecular Weight | 566.665 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCN(CC)C1=CC=C(C=C1)C(=C2C=CC(C=C2)=[N+](CC)CC)C3=C(C=CC(=C3)S([O-])(=O)=O)S([O-])(=O)=O
InChI
InChIKey=NLUFDZBOHMOBOE-UHFFFAOYSA-M
InChI=1S/C27H32N2O6S2.Na/c1-5-28(6-2)22-13-9-20(10-14-22)27(21-11-15-23(16-12-21)29(7-3)8-4)25-19-24(36(30,31)32)17-18-26(25)37(33,34)35;/h9-19H,5-8H2,1-4H3,(H-,30,31,32,33,34,35);/q;+1/p-1
Molecular Formula | C27H31N2O6S2 |
Molecular Weight | 543.675 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Isosulfan Blue is a synthetic visual lymphatic imaging agent. Injected into the periphery of the tumor site, isosulfan blue localizes to the lymphatic system and aids in the surgical identification of tumor sentinel nodes which stain blue. The chemical name of isosulfan blue is N-[4-[[4-(diethylamino)phenyl] (2,5-disulfophenyl) methylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium hydroxide, inner salt, sodium salt. Isosulfan blue is a greenish blue color hygroscopic powder. Isosulfan blue injection 1% is a contrast agent for the delineation of lymphatic vessels. Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities.
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11.03 mg/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29141490/ |
938 mmol/kg single, subcutaneous dose: 938 mmol/kg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
ISOSULFAN BLUE plasma | Mus musculus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.9 mg × h/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29141490/ |
938 mmol/kg single, subcutaneous dose: 938 mmol/kg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
ISOSULFAN BLUE plasma | Mus musculus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.14 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29141490/ |
938 mmol/kg single, subcutaneous dose: 938 mmol/kg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
ISOSULFAN BLUE plasma | Mus musculus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
99% |
unknown, subcutaneous |
ISOSULFAN BLUE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3 mL single, subcutaneous (max) Studied dose Dose: 3 mL Route: subcutaneous Route: single Dose: 3 mL Sources: |
unhealthy Health Status: unhealthy Condition: lymphedema of the extremities Sources: |
Other AEs: Hypersensitivity, Respiratory distress... Other AEs: Hypersensitivity (2%) Sources: Respiratory distress (grade 4) Shock (grade 4) Angioedema (grade 4) Urticaria (grade 4) Pruritus (grade 4) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypersensitivity | 2% | 3 mL single, subcutaneous (max) Studied dose Dose: 3 mL Route: subcutaneous Route: single Dose: 3 mL Sources: |
unhealthy Health Status: unhealthy Condition: lymphedema of the extremities Sources: |
Angioedema | grade 4 | 3 mL single, subcutaneous (max) Studied dose Dose: 3 mL Route: subcutaneous Route: single Dose: 3 mL Sources: |
unhealthy Health Status: unhealthy Condition: lymphedema of the extremities Sources: |
Pruritus | grade 4 | 3 mL single, subcutaneous (max) Studied dose Dose: 3 mL Route: subcutaneous Route: single Dose: 3 mL Sources: |
unhealthy Health Status: unhealthy Condition: lymphedema of the extremities Sources: |
Respiratory distress | grade 4 | 3 mL single, subcutaneous (max) Studied dose Dose: 3 mL Route: subcutaneous Route: single Dose: 3 mL Sources: |
unhealthy Health Status: unhealthy Condition: lymphedema of the extremities Sources: |
Shock | grade 4 | 3 mL single, subcutaneous (max) Studied dose Dose: 3 mL Route: subcutaneous Route: single Dose: 3 mL Sources: |
unhealthy Health Status: unhealthy Condition: lymphedema of the extremities Sources: |
Urticaria | grade 4 | 3 mL single, subcutaneous (max) Studied dose Dose: 3 mL Route: subcutaneous Route: single Dose: 3 mL Sources: |
unhealthy Health Status: unhealthy Condition: lymphedema of the extremities Sources: |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:25:43 UTC 2023
by
admin
on
Fri Dec 15 16:25:43 UTC 2023
|
Record UNII |
39N9K8S2A4
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C461
Created by
admin on Fri Dec 15 16:25:43 UTC 2023 , Edited by admin on Fri Dec 15 16:25:43 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
50108
Created by
admin on Fri Dec 15 16:25:43 UTC 2023 , Edited by admin on Fri Dec 15 16:25:43 UTC 2023
|
PRIMARY | |||
|
SUB182640
Created by
admin on Fri Dec 15 16:25:43 UTC 2023 , Edited by admin on Fri Dec 15 16:25:43 UTC 2023
|
PRIMARY | |||
|
27863
Created by
admin on Fri Dec 15 16:25:43 UTC 2023 , Edited by admin on Fri Dec 15 16:25:43 UTC 2023
|
PRIMARY | RxNorm | ||
|
39N9K8S2A4
Created by
admin on Fri Dec 15 16:25:43 UTC 2023 , Edited by admin on Fri Dec 15 16:25:43 UTC 2023
|
PRIMARY | |||
|
C025484
Created by
admin on Fri Dec 15 16:25:43 UTC 2023 , Edited by admin on Fri Dec 15 16:25:43 UTC 2023
|
PRIMARY | |||
|
CHEMBL1615783
Created by
admin on Fri Dec 15 16:25:43 UTC 2023 , Edited by admin on Fri Dec 15 16:25:43 UTC 2023
|
PRIMARY | |||
|
8071
Created by
admin on Fri Dec 15 16:25:43 UTC 2023 , Edited by admin on Fri Dec 15 16:25:43 UTC 2023
|
PRIMARY | |||
|
734902
Created by
admin on Fri Dec 15 16:25:43 UTC 2023 , Edited by admin on Fri Dec 15 16:25:43 UTC 2023
|
PRIMARY | |||
|
39N9K8S2A4
Created by
admin on Fri Dec 15 16:25:43 UTC 2023 , Edited by admin on Fri Dec 15 16:25:43 UTC 2023
|
PRIMARY | |||
|
DTXSID8057805
Created by
admin on Fri Dec 15 16:25:43 UTC 2023 , Edited by admin on Fri Dec 15 16:25:43 UTC 2023
|
PRIMARY | |||
|
68238-36-8
Created by
admin on Fri Dec 15 16:25:43 UTC 2023 , Edited by admin on Fri Dec 15 16:25:43 UTC 2023
|
PRIMARY | |||
|
100000168999
Created by
admin on Fri Dec 15 16:25:43 UTC 2023 , Edited by admin on Fri Dec 15 16:25:43 UTC 2023
|
PRIMARY | |||
|
4503
Created by
admin on Fri Dec 15 16:25:43 UTC 2023 , Edited by admin on Fri Dec 15 16:25:43 UTC 2023
|
PRIMARY | |||
|
DB09136
Created by
admin on Fri Dec 15 16:25:43 UTC 2023 , Edited by admin on Fri Dec 15 16:25:43 UTC 2023
|
PRIMARY | |||
|
C1386
Created by
admin on Fri Dec 15 16:25:43 UTC 2023 , Edited by admin on Fri Dec 15 16:25:43 UTC 2023
|
PRIMARY | |||
|
m10387
Created by
admin on Fri Dec 15 16:25:43 UTC 2023 , Edited by admin on Fri Dec 15 16:25:43 UTC 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |